A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
Condition: Ocular Inflammation and Pain Interventions: Drug: APP13007, 0.05%; Drug: APP13007, 0.1%; Drug: APP13007 Placebo, 0.05%; Drug: APP13007 Placebo, 0.1% Sponsor: Formosa Pharmaceuticals, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials